Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart
  • Log out

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions

Multi-level differential network analysis of COPD exacerbations

Guillaume Noell, Borja G. Cosío, Rosa Faner, Eduard Monsó, German Peces-Barba, Alfredo de Diego, Cristobal Esteban, Joaquim Gea, Robert Rodriguez-Roisin, Marian Garcia-Nuñez, Francisco Pozo-Rodriguez, Susana G. Kalko, Alvar Agustí
European Respiratory Journal 2017 50: 1700075; DOI: 10.1183/13993003.00075-2017
Guillaume Noell
1CIBER Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Barcelona, Spain
2Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
12Joint lead authors
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Borja G. Cosío
1CIBER Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Barcelona, Spain
3Servei Pneumologia, Hospital Universitari Son Espases-IdISBa, Mallorca, Spain
12Joint lead authors
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Borja G. Cosío
Rosa Faner
1CIBER Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Barcelona, Spain
2Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
12Joint lead authors
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eduard Monsó
1CIBER Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Barcelona, Spain
4Servei Pneumologia, Hospital Parc Taulí, Sabadell, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
German Peces-Barba
5Servicio Neumología, Fundación Jimenez Díaz, Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alfredo de Diego
6Servicio Neumología, Hospital Universitario La Fe, Valencia, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cristobal Esteban
7Servicio Neumología, Hospital Galdakao, Bizkaia, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joaquim Gea
1CIBER Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Barcelona, Spain
8Servei de Pneumologia, Hospital del Mar - IMIM. DCEXS, Universitat Pompeu Fabra, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Rodriguez-Roisin
1CIBER Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Barcelona, Spain
2Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
9Departament de Medicina, Universitat de Barcelona, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marian Garcia-Nuñez
1CIBER Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Barcelona, Spain
4Servei Pneumologia, Hospital Parc Taulí, Sabadell, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francisco Pozo-Rodriguez
1CIBER Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Barcelona, Spain
10Hospital Universitario 12 de Octubre, Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susana G. Kalko
2Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alvar Agustí
1CIBER Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Barcelona, Spain
2Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
9Departament de Medicina, Universitat de Barcelona, Barcelona, Spain
11Respiratory Institute, Hospital Clinic, University of Barcelona, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: AAGUSTI@clinic.cat
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Patients with chronic obstructive pulmonary disease (COPD) often suffer episodes of exacerbation (ECOPD) that impact negatively the course of their disease. ECOPD are heterogeneous events of unclear pathobiology and non-specific diagnosis. Network analysis is a novel research approach that can help unravelling complex biological systems. We hypothesised that the comparison of multi-level (i.e., clinical, physiological, biological, imaging and microbiological) correlation networks determined during ECOPD and convalescence can yield novel patho-biologic information.

In this proof-of-concept study we included 86 patients hospitalised because of ECOPD in a multicentre study in Spain. Patients were extensively characterised both during the first 72 h of hospitalisation and during clinical stability, at least 3 months after hospital discharge.

We found that 1) episodes of ECOPD are characterised by disruption of the network correlation observed during convalescence; and 2) a panel of biomarkers that include increased levels of dyspnoea, circulating neutrophils and C-reactive protein (CRP) has a high predictive value for ECOPD diagnosis (AUC 0.97).

We conclude that ECOPD 1) are characterised by disruption of network homeokinesis that exists during convalescence; and 2) can be identified objectively by using a panel of three biomarkers (dyspnoea, circulating neutrophils and CRP levels) frequently determined in clinical practice.

Abstract

This is the first study to investigate COPD exacerbations using multi-level differential network analysis http://ow.ly/uYlW30eMpwR

Introduction

Patients with chronic obstructive pulmonary disease (COPD) often suffer episodes of exacerbation (ECOPD) that impact negatively their health status and prognosis [1]. The pathogenesis of these episodes is not entirely understood, but it is presumed complex and heterogeneous [2–4]. Their diagnosis relies mostly on symptom perception by the patient [5] and their prevention and treatment is, by and large, empiric [1].

Network analysis is an integrative research strategy well suited for the investigation of heterogeneous and complex diseases [6, 7] such as COPD [8–14]. We hypothesised that multi-level differential network analysis (MLDNA), a novel analytical method that involves the comparison of clinical, physiological, biological, imaging and microbiological (i.e. multi-level) correlation networks determined during ECOPD and clinical stability, can provide new insights into the pathobiology and diagnosis of ECOPD [15, 16]. Accordingly, in this proof-of-concept study we used MLDNA, for the first time to our knowledge, to 1) compare the multi-level network structure determined during ECOPD and convalescence; and 2) identify a panel of specific ECOPD biomarkers.

Methods

Methods are described in detail in the supplementary material.

Study design and ethics

This observational, prospective proof-of-concept study was carried out in seven tertiary referral hospitals in Spain (www.clinicaltrials.gov: NCT01750658). Patients were recruited and studied during the first 72 h of hospitalisation because of ECOPD, and investigated again during convalescence, at least 3 months after hospital discharge. The Institutional Review Boards of participating institutions approved the study, and participants gave their informed consent.

Patients

All patients were older than 45 years, current or former smokers (>10 pack-years) and had COPD (and ECOPD) according to the Global Initiative for Chronic Obstructive Lung Disease criteria [1]. In order to homogenise the studied population as much as possible, pneumonia on chest radiography, the presence of severe comorbidity driving the clinical presentation of the patient and/or need of (invasive or noninvasive) mechanical ventilation were exclusion criteria. We initially attempted to recruit patients who had not received oral steroids and/or antibiotic treatment in the community before hospitalisation. Yet, this strategy limited recruitment a lot, so we decided to adopt a more pragmatic design and exclude patients who received oral steroids before hospitalisation (with a potential rapid anti-inflammatory effect) but not those who may have received antibiotics (which may take longer to affect microbiological results). A total of 14 patients (16%) were included in the analysis despite they received antibiotic treatment in the community before hospitalisation.

Measurements

Clinical, functional, biological, microbiological and imaging variables were recorded following standard procedures, as detailed in the supplementary material.

Data analysis

Descriptive statistics

Because many variables were non-normally distributed, the results are presented as median (and 95% confidence intervals) or proportions. Likewise, because not all measurements were available in all patients in both visits, to maximise the potential of available information, the results at ECOPD and convalescence were compared using pairwise statistics (paired Wilcoxon or Chi-squared tests for continuous and discrete variables, respectively). Participants with missing data were discarded on a per-variable basis, such that no value imputation was required. We used false discovery rates (FDRs) to account for multiple comparisons [17]. All analyses were performed using R [18].

Multi-level correlation networks

We built multi-level correlation (Spearman) networks that integrate quantitative and qualitative clinical, functional, biological, microbiological and imaging variables (independently for ECOPD and convalescence) using R [18], and we graphed them with Cytoscape [19].

Module finding

We used the fast-greedy community algorithm to identify network modules on the basis of their module modularity (MM) score, so those with more dense internal connections and fewer external links get higher MM scores [20, 21].

Differential network analysis

To compare multilevel correlation networks at ECOPD and convalescence we 1) nominally contrasted the variables and modules identified under both clinical circumstances; 2) estimated the mean “density” of networks determined at ECOPD and convalescence by comparing (Wilcoxon test) the number of nodes, and the average number of edges per node (node degree, k) during ECOPD and convalescence [6]; and, 3) used Monte Carlo permutation tests [22] to identify those Spearman correlations that were significantly different between ECOPD and convalescence.

ECOPD biomarkers

We defined as “outliers” at ECOPD those values below or above the 5th or 95th percentiles, respectively, of the same variable at convalescence, and we identified those ECOPD variables with a significant (bootstrapping FDR <0.05) number of outliers. To identify potential ECOPD biomarkers, we calculated receiver operating characteristic (ROC) curves considering all values determined at ECOPD and convalescence and excluding missing data on a per-variable basis.

Results

We studied 86 patients at ECOPD (mean±sd age of 67±9 years). As shown in figure 1, 19 patients were lost for follow-up, so we could study 67 of them at convalescence. Table 1 presents the main characteristics of participants at both time points.

FIGURE 1
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1

Consort diagram of the study.

View this table:
  • View inline
  • View popup
TABLE 1

Clinical, physiologic, imaging, biological and microbiological data determined during exacerbation of chronic obstructive pulmonary disease (ECOPD) and convalescence

Observations at ECOPD

Besides the expected observations during ECOPD (dyspnoea, tachypnoea, tachycardia, respiratory failure) some other salient findings were (table 1): 1) elevated blood glucose levels, likely to be in relation to the generalised use of systemic steroids in the management of ECOPD [1, 23]; 2) echography identified the presence of pulmonary hypertension in 21.2% of patients and right chamber enlargement in 19.1%, but no patient suffered heart failure with low ejection fraction; 3) computed tomography (CT) emphysema was present in 56.7% of patients, bronchiectasis in 17.5% and, interestingly, alveolar infiltrates (not seen in chest radiography films) in 23.8%. Pulmonary embolism was found in 1.5% of individuals; and 4) in patients producing spontaneous sputum (77.9%), bacterial culture was positive for potential pathogenic microorganisms (PPMs) in 19.4% of them, whereas viruses were detected by a positive sputum virus in 30.9%. A total of 37.8% of patients were positive for sputum PPMs and/or viruses (table 1). More detailed microbiologic information can be found in the supplementary material.

Changes at convalescence

The main changes from ECOPD to convalescence (highlighted in bold type in table 1) included 1) improved dyspnoea; 2) reduced heart and respiratory rate; 3) reduced serum levels of glucose and urea; 4) improved pulmonary gas exchange without significant changes in spirometric variables; 5) reduced total leukocyte count, with lower circulating neutrophils and higher lymphocyte and eosinophil proportions; 6) reduced concentration of acute phase reactants (C-reactive protein (CRP) and fibrinogen) with increased levels of serum amyloid A (SAA). Other systemic inflammatory markers did not change significantly or changed marginally; and, finally, 7) neither bacterial load, viral load nor inflammatory markers changed significantly.

Multi-level differential network analysis

Figure 2 shows the correlation networks determined at ECOPD and convalescence, and table 2 their quantitative comparison. The main observations were 1) the number of nodes at ECOPD and convalescence was similar (51 versus 47), but the convalescence network was significantly denser, as shown by the higher total number of edges, a significantly higher node degree (k), and lower modularity; 2) there were six hubs with a Kleinberg score >0.8 in the ECOPD network and four in the convalescence one. All of the former correspond to sputum inflammatory markers whereas all of the latter correspond to lung function variables; 3) there were five modules at ECOPD and six at convalescence (figure 2, blue areas). All of them appear relatively homogeneous in terms of their biological content, since the majority contained nodes of similar functional category (see colour codes in figure 2). A detailed description of each of these modules is provided in the supplementary material; and 4) the comparison of both networks showed a higher density of significantly different Spearman correlations at convalescence than during ECOPD (table 2 and figure 3) and that more than half of these differential correlations linked different modules (figure 3): at ECOPD, TNF-α was the node with more differential links (n=4) whereas at convalescence these were TGF-β (n=6), KCO (n=5), PAFI (n=5), PaO2 (n=5) and heart rate (n=4). All in all, these observations suggest that the network “perturbation” induced by ECOPD involves a reduction in module co-regulation (i.e. co-occurrence).

FIGURE 2
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 2

Correlation networks at exacerbation of chronic obstructive pulmonary disease (ECOPD) and convalescence. Node colours identify their category (see colour codes). Links between nodes indicate the existence of a statistically significant correlation between them (positive, continuous lines; negative, dashed lines), whereas their width is proportional to the strength of such correlation. Blue shaded areas indicate the different modules (MM) identified by the fast-greedy community algorithm used, so modules with a higher proportion of internal connections get higher MM scores. For further explanations, see text.

View this table:
  • View inline
  • View popup
TABLE 2

Comparison of correlation networks determined at exacerbation of chronic obstructive pulmonary disease (ECOPD) and convalescence

FIGURE 3
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 3

Same correlation networks presented in figure 2 now highlighting those that were significantly different at exacerbation of chronic obstructive pulmonary disease (ECOPD) and convalescence (i.e. Rho ECOPD≠Rho convalescence) by green or blue lines (see legend for Rho correspondence). For further explanations, see text.

ECOPD biomarkers: outlier analysis

To investigate potential ECOPD biomarkers, we 1) identified 16 variables (12% of the total number of variables analysed in the study (table 1)) with a significant proportion of ECOPD “outliers”, this is a significant (FDR p-value<0.05) proportion of variable values outside the 5th to 95th percentile range of the same variable determined at convalescence (by Monte-Carlo ECOPD/convalescence permutation test on the statistic (% outliers at ECOPD – % outliers at convalescence)); 2) assessed the extent to what these outliers co-occur in the same patients. To this end, we built a co-occurrence network (figure 4) where each node correspond to one of these 16 variables, node size to the proportion of outliers at ECOPD (as indicated by the percentage for each of them), node shape (up or down triangle) indicates if a given variable is higher (up) or lower (down) at ECOPD, and edge colours represent the proportion of co-occurrence between two given nodes (see keys). Circulating lymphocytes and neutrophils were co-altered (albeit in opposite directions) in more than 75% of the exacerbated patients (blue edge), and eosinophils, dyspnoea and glucose levels in 50–75% of patients (green edges; note also the different triangle shapes). The remaining nodes co-occurred in 25–50% of patients (orange edges); 3) explored the capacity of these 16 variables to predict ECOPD by ROC analysis, and identified a subset of seven of them with an area under the curve (AUC) >0.8. Figure 5a presents the scatter distribution of these seven variables and their individualised ROC profile and AUC (figure 5b); of note, although all of them had a large number of outliers at ECOPD (red symbols), a proportion of values at ECOPD still remained within the 5th to 95th range (horizontal lines) determined at convalescence (figure 5a), likely reflecting the heterogeneity of ECOPD episodes; and, finally, 4) included these seven variables in a general linear mixed model to identify the best diagnostic biomarker panel of ECOPD. We found that the combination of dyspnoea severity, raised circulating neutrophils and elevated CRP levels had an AUC of 0.97 (95% CI 0.95–1) to diagnose ECOPD (figure 5c). Finally we calculated what different combinations of abnormal values of these three variables gave the better specificity, sensitivity, positive and negative prediction values for the diagnosis of an ECOPD (table 3). We observed that dyspnoea levels ≥5 (on an analogue visual score that ranges from 0 to 10), CRP ≥3 mg·L−1 and ≥70% circulating neutrophils had a specificity of 0.96, a sensitivity of 0.901, negative predictive value of 0.88 and positive predictive value of 0.97 for the identification of ECOPD.

FIGURE 4
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 4

Outlier correlation network. Nodes represent the 16 identified variables with a significant proportion of outliers at exacerbation of chronic obstructive pulmonary disease (ECOPD). Node size is proportional to the percentage of outlier values (see digits inside nodes). Edges represent shared proportions (see colour codes). The shape of the triangle (upwards or downwards) indicates that the proportion of ECOPD outliers is lower or higher than the 5th or 95th convalescence percentiles, respectively.

FIGURE 5
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 5

a) Scatter plot of seven continuous variables with a significant (bootstrapping FDR p-value <0.05) proportion of exacerbation of chronic obstructive pulmonary disease (ECOPD) outliers (<5TH or >95th percentiles (horizontal lines) at convalescence. Red symbols represent outlier values; blue symbols represent values within the convalescence 5th to 95th percentiles. b) Receiver operating characteristic curves and corresponding area under the curve (AUC) values for each of these 7 potential diagnostic biomarkers of ECOPD identified in a) with an AUC >0.8; c) When the seven variables identified in b) were combined in a general linear mixed model, the best panel of biomarkers to predict ECOPD (AUC 0.97) included circulating neutrophils, C-reactive protein levels and dyspnoea. For further explanations, see text.

View this table:
  • View inline
  • View popup
TABLE 3

Specificity, sensitivity, negative (NPV) and positive predictive value (PPV) of a logistic regression model that includes different cut-off values of dyspnoea, C-reactive protein (CRP) and circulating neutrophil for the diagnosis of chronic obstructive pulmonary disease exacerbation (ECOPD)

Discussion

This proof-of-concept study develops and applies for the first time MLDNA to a relevant, complex and heterogeneous clinical problem (ECOPD). By doing so it shows that 1) ECOPD episodes are characterised by fragmentation of the correlation network observed during clinical stability, suggesting loss of system control and reduced resilience during ECOPD [24, 25]; and 2) a panel of biomarkers that includes dyspnoea (≥5 on an analogue visual score from 0 to 10), CRP level (≥3 mg·L−1) and ≥70% circulating neutrophils had an extremely high value (AUC 0.97) for the diagnosis of ECOPD.

Previous studies

Many studies have previously described the clinical, physiological, biological and microbiological characteristics of ECOPD [26]. By and large, our clinical observations are in keeping with them, but some deserve specific comment. During ECOPD 1) a substantial number of patients had pulmonary hypertension and right chamber enlargement, in keeping with recent reports [27], but we did not identify patients with low ejection fraction heart failure [28]; and 2) CT found evidence of pulmonary embolism in only 1.5% of patients [29, 30] but, in contrast, alveolar infiltrates (not seen in chest radiographs) were identified in about a quarter of patients, as reported recently too [31]. These alveolar infiltrates can correspond to pneumonic condensations not apparent in plain chest radiographs and/or areas of local inflammation/oedema. At convalescence many (but not all) abnormalities observed during ECOPD improved. Of note, 3) even though dyspnoea and pulmonary gas exchange improved, spirometric changes only showed a statistically nonsignificant trait to improvement, which is at variance with other previous, smaller studies [32–34]; 4) as expected, several markers of systemic inflammation (total leukocyte count and levels of circulating neutrophils, CRP and fibrinogen) were reduced at convalescence. Of note, however, only 5.7% of patients showed >2% circulating eosinophils during ECOPD, and this proportion increased up to 54.7% at convalescence. This is at variance with reports from other centres, where between 25% and 50% of the patients have >2% circulating eosinophils during ECOPD [3, 35, 36]. We do not have a clear explanation for these discrepancies but regional differences may play a role [37]; and, finally, 5) in patients producing spontaneous sputum, the prevalence of PPM and/or viruses did not change at convalescence. Given that bronchial colonisation in clinically stable COPD patients that produce spontaneous sputum is common [38], this may have contributed to explain this lack of statistically significant changes.

Interpretation of novel results

Homeokinetic disruptive effects of ECOPD

Homeokinesis has been defined as “the ability of an organism to maintain a highly organised internal environment fluctuating within acceptable limits in a far from equilibrium state” [24, 25]. ECOPD episodes appear to be characterised by disrupted homeokinesis since, during clinical stability we observed a dense and well-connected correlation network with physiologically meaningful modules whereas, during ECOPD, although these modules mostly remain their connections become disrupted to a large extent (figure 2, table 2). Specifically, during clinical stability a central module (MM7), which basically includes all lung function parameters, was closely co-regulated with other modules that include pulmonary and systemic inflammatory markers (MM8, MM9, MM10) as well as a general biochemical module (MM6). By contrast, during ECOPD, the system becomes more fragmented, the sputum inflammation module (MM5) appears isolated, and systemic inflammatory markers are also less well coordinated and distributed across two different modules (MM3 and MM4). That microbiological nodes appear isolated from the main network during ECOPD probably reflects the heterogeneity of these ECOPD. Finally, the Monte Carlo permutation test [22] also identified more significantly different Spearman correlations at convalescence than during ECOPD (figure 3). All in all, these observations suggest that episodes of ECOPD are characterised by breakdown of the normal homeokinetic characteristics of the system with presumably less system control and resilience [24, 25].

A panel of biomarkers for the diagnosis of ECOPD

The diagnosis of ECOPD currently relies on the patient's perception of increased symptoms (mostly dyspnoea) [1, 5]. Yet, recent research has shown that dyspnoea perception vary between patients with frequent and infrequent exacerbations [39]. Thus, having an objective way to diagnose ECOPD is of great clinical relevance [2]. Our results indicate that the combination of increased dyspnoea (≥5) and raised levels of circulating neutrophils (≥70%) and CRP (≥3 mg·L−1) has an excellent value for the diagnosis of ECOPD (AUC 0.97) (figure 5c). Although the methodology we used is different, results are similar to those reported by Hurst et al. [40], who showed that elevated CRP levels were the best diagnostic biomarker for ECOPD, although their diagnosis accuracy was suboptimal (AUC 0.73); however, their combination with a major exacerbation symptom (dyspnoea, sputum volume or sputum purulence) significantly increased the AUC to 0.88 (p<0.0001) [40]. Our results extend these observations further by showing that this can be further improved (AUC 0.97) by considering too the number of circulating neutrophils. The potential diagnostic utility of this biomarker panel (as well as its specific cut-off values) will have to be validated prospectively in other cohorts, but it may greatly help to advance clinical research in this area by offering for the first time an objective diagnostic tool of ECOPD. Needless to say that increased dyspnoea, elevated CRP and leukocytosis can also occur in other clinical circumstances that may not even arise from the lungs (e.g. cholecystitis, pneumonia or sickle cell crisis, among others). Therefore, the clinical context in which these three biomarkers can contribute to the diagnosis of ECOPD is of paramount importance. Finally, using unbiased cluster analysis of 182 ECOPD episodes, Bafadhel et al. [3] recently provided convincing evidence of the heterogeneity of such episodes. Unfortunately, the relatively small sample size of our cohort (n=86) limits this type of analysis in our cohort.

Strengths and limitations

The development and application, for the first time to our knowledge, of a new analytical approach (e.g. MLDNA) to get further insight into the complexity of a relevant clinical problem like ECOPD is a clear strength of our study since it provides novel, integrated, dynamic and holistic information on this frequent condition. Importantly, it also paves the way for MLDNA to be applied to other complex biological conditions in respiratory medicine and elsewhere [6, 8, 16, 41, 42].

On the other hand, several potential limitations deserve comment. First, we included in the study a slightly lower number of patients (n=86) than anticipated (n=100; www.clinicaltrials.gov: NCT01750658), and not all measurements were available in all patients for comparison between ECOPD and convalescence. This is why we consider our study as proof-of-concept and we acknowledge that it requires validation in larger cohorts. Second, we studied severe (hospitalised) ECOPD, so our results are not directly generalisable to other milder forms of ECOPD. Third, some clinical variables, such as cough and sputum colour, were not registered. Fourth, it is not clear how much the initiation of systemic corticosteroids, before the collection of biological samples (within 72 h after admission) might have modified the inflammatory profile of ECOPD. Yet, it is of note that we excluded patients who received oral corticosteroid treatment before hospitalisation. Finally, patients present to hospital at various time points in the evolution of an ECOPD. All in all, we acknowledge that the results of this study will have to be confirmed in future studies, since the exclusion of severe co-morbidity, pneumonia, relatively small sample size and study of hospitalised patients (not ambulatory ECOPD) may restricts the generalisability of our observations.

Conclusions

By using a novel analytical strategy (MLDNA), this study shows that ECOPD 1) are characterised by disruption of network homeokinesis observed during clinical stability; and 2) in the appropriate clinical context, ECOPD can be objectively identified by a panel of three biomarkers (dyspnoea, circulating neutrophils and CRP) commonly measured in clinical practice.

Supplementary material

Supplementary Material

Please note: supplementary material is not edited by the Editorial Office, and is uploaded as it has been supplied by the author.

Supplementary material ERJ-00075-2017_Supplement

Disclosures

Supplementary Material

A. Agusti ERJ-00075-2017_Agusti

B.G. Cosío ERJ-00075-2017_Cosio

R. Rodriguez-Roisin ERJ-00075-2017_Rodriguez-Roisin

Acknowledgements

The authors thank participating patients for their willingness to contribute to medical research, and field attending physicians and nurses for their dedication and excellent care. The authors also thank Joan Soriano and Dolores Guerrero for their help in the start-up of the project, and Jørgen Vestbo, Judith Garcia-Aymerich, Josep Maria Antó and Peter J. Barnes for helpful suggestions.

Footnotes

  • This article has supplementary material available from erj.ersjournals.com

  • This study is registered at www.clinicaltrials.gov as NCT01750658.

  • Support statement: Supported, in part, by Fondo de Investigación Sanitaria, Instituto Carlos III (PI 05/1463 and PI 15/00799), CIBERES, an unrestricted grant from GlaxoSmithKline, a PhD scholar grant from the Catalan Government (FI-2016) and CERCA Programme/Generalitat de Catalunya. Funding information for this article has been deposited with the Crossref Funder Registry.

  • Conflict of interest: Disclosures can be found alongside this article at erj.ersjournals.com

  • Received January 13, 2017.
  • Accepted June 26, 2017.
  • Copyright ©ERS 2017

References

  1. ↵
    1. Vogelmeier C,
    2. Agusti A,
    3. Anzueto A
    , et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2017 Report). 2017 http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/ Date last accessed: November 16, 2016.
  2. ↵
    1. Celli BR,
    2. Decramer M,
    3. Wedzicha JA
    , et al. An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. Eur Respir J 2015; 45: 879–905.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Bafadhel M,
    2. McKenna S,
    3. Terry S
    , et al. Acute exacerbations of COPD: identification of biological clusters and their biomarkers. Am J Respir Crit Care Med 2011; 184: 662–671.
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. Beghe B,
    2. Verduri A,
    3. Roca M
    , et al. Exacerbation of respiratory symptoms in COPD patients may not be exacerbations of COPD. Eur Respir J 2013; 41: 993–995.
    OpenUrlFREE Full Text
  5. ↵
    1. Rodriguez-Roisin R
    . Toward a consensus definition for COPD exacerbations. Chest 2000; 117: Suppl. 2, 398S–401S.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    1. Barabasi AL,
    2. Gulbahce N,
    3. Loscalzo J
    . Network medicine: a network-based approach to human disease. Nat Rev Genet 2011; 12: 56–68.
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    1. Diez D,
    2. Agusti A,
    3. Wheelock CE
    . Network analysis in the investigation of chronic respiratory diseases: from basics to application. Am J Respir Crit Care Med 2014; 190: 981–988.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Menche J,
    2. Sharma A,
    3. Cho M
    , et al. A diVIsive Shuffling Approach (VIStA) for gene expression analysis to identify subtypes in chronic obstructive pulmonary disease. BMC Syst Biol 2014; 8: Suppl. 2, S8.
    OpenUrlPubMed
    1. Rennard SI,
    2. Locantore N,
    3. Delafont B
    , et al. Identification of five COPD subgroups with different prognoses in the ECLIPSE cohort using cluster analysis. Ann Am Thorac Soc 2015.
    1. Faner R,
    2. Gutierrez-Sacristan A,
    3. Castro-Acosta A
    , et al. Molecular and clinical diseasome of comorbidities in exacerbated COPD patients. Eur Respir J 2015; 46: 1001–1010.
    OpenUrlAbstract/FREE Full Text
    1. Faner R,
    2. Agustí A
    . Network analysis: a way forward for understanding COPD multimorbidity. Eur Respir J 2015; 46: 591–592.
    OpenUrlAbstract/FREE Full Text
    1. Faner R,
    2. Cruz T,
    3. López-Giraldo A
    , et al. Network medicine, multimorbidity and the lung in the elderly. Eur Respir J 2014; 44: 775–788.
    OpenUrlAbstract/FREE Full Text
    1. Grosdidier S,
    2. Ferrer A,
    3. Faner R
    , et al. Network medicine analysis of COPD multimorbidities. Respir Res 2014; 15: 111.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Faner R,
    2. Cruz T,
    3. Casserras T
    , et al. Network analysis of lung transcriptomics reveals a distinct B cell signature in emphysema. Am J Respir Crit Care Med 2016; 193: 1242–1253.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Gustafsson M,
    2. Edstrom M,
    3. Gawel D
    , et al. Integrated genomic and prospective clinical studies show the importance of modular pleiotropy for disease susceptibility, diagnosis and treatment. Genome Med 2014; 6: 17.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Gustafsson M,
    2. Nestor C,
    3. Zhang H
    , et al. Modules, networks and systems medicine for understanding disease and aiding diagnosis. Genome Med 2014; 6: 82.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Benjamini Y,
    2. Hochberg Y
    . Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B (Methodological) 1995; 57: 289–300.
    OpenUrl
  13. ↵
    R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria, 2015.
  14. ↵
    1. Shannon P,
    2. Markiel A,
    3. Ozier O
    , et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003; 13: 2498–2504.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Newman ME,
    2. Girvan M
    . Finding and evaluating community structure in networks. Phys Rev E Stat Nonlin Soft Matter Phys 2004; 69: 026113.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Su G,
    2. Kuchinsky A,
    3. Morris JH
    , et al. GLay: community structure analysis of biological networks. Bioinformatics 2010; 26: 3135–3137.
    OpenUrlCrossRefPubMedWeb of Science
  17. ↵
    1. Fishman GS
    . Monte Carlo: concepts, algorithms and applications. New York, Springer, 1995.
  18. ↵
    1. Davies L,
    2. Angus RM,
    3. Calverley PM
    . Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet 1999; 354: 456–460.
    OpenUrlCrossRefPubMedWeb of Science
  19. ↵
    1. Macklem PT
    . Emergent phenomena and the secrets of life. J Appl Physiol 2008; 104: 1844–1846.
    OpenUrlCrossRefPubMed
  20. ↵
    1. Macklem PT,
    2. Seely A
    . Towards a definition of life. Perspect Biol Med 2010; 53: 330–340.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Wedzicha JA,
    2. Singh R,
    3. Mackay AJ
    . Acute COPD exacerbations. Clin Chest Med 2014; 35: 157–163.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Freixa X,
    2. Portillo K,
    3. Pare C
    , et al. Echocardiographic abnormalities in patients with COPD at their first hospital admission. Eur Respir J 2013; 41: 784–791.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Singanayagam A,
    2. Schembri S,
    3. Chalmers JD
    . Predictors of mortality in hospitalized adults with acute exacerbation of chronic obstructive pulmonary disease. Ann Am Thorac Soc 2013; 10: 81–89.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Roca M,
    2. Verduri A,
    3. Corbetta L
    , et al. Mechanisms of acute exacerbation of respiratory symptoms in chronic obstructive pulmonary disease. Eur J Clin Invest 2013; 43: 510–521.
    OpenUrlCrossRefPubMed
  25. ↵
    1. Tillie-Leblond I,
    2. Marquette CH,
    3. Perez T
    , et al. Pulmonary embolism in patients with unexplained exacerbation of chronic obstructive pulmonary disease: prevalence and risk factors. Ann Intern Med 2006; 144: 390–396.
    OpenUrlCrossRefPubMedWeb of Science
  26. ↵
    1. Cheng T,
    2. Wan H,
    3. Cheng Q
    , et al. Computed tomography manifestation of acute exacerbation of chronic obstructive pulmonary disease: A pilot study. Exp Ther Med 2016; 11: 519–529.
    OpenUrl
  27. ↵
    1. Stevenson NJ,
    2. Walker PP,
    3. Costello RW
    , et al. Lung mechanics and dyspnea during exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 172: 1510–1516.
    OpenUrlCrossRefPubMedWeb of Science
    1. Parker CM,
    2. Voduc N,
    3. Aaron SD
    , et al. Physiological changes during symptom recovery from moderate exacerbations of COPD. Eur Respir J 2005; 26: 420–428.
    OpenUrlAbstract/FREE Full Text
  28. ↵
    1. Cote CG,
    2. Dordelly LJ,
    3. Celli BR
    . Impact of COPD exacerbations on patient-centered outcomes. Chest 2007; 131: 696–704.
    OpenUrlCrossRefPubMedWeb of Science
  29. ↵
    1. Bafadhel M,
    2. McKenna S,
    3. Terry S
    , et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med 2012; 186: 48–55.
    OpenUrlCrossRefPubMedWeb of Science
  30. ↵
    1. Bafadhel M,
    2. Davies L,
    3. Calverley PMA
    , et al. Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis. Eur Respir J 2014; 44: 789–791.
    OpenUrlFREE Full Text
  31. ↵
    1. Saha S,
    2. Brightling CE
    . Eosinophilic airway inflammation in COPD. Int J Chron Obstruct Pulmon Dis 2006; 1: 39–47.
    OpenUrlPubMed
  32. ↵
    1. Bandi V,
    2. Apicella MA,
    3. Mason E
    , et al. Nontypeable Haemophilus influenzae in the lower respiratory tract of patients with chronic bronchitis. Am J Respir Crit Care Med 2001; 164: 2114–2119.
    OpenUrlCrossRefPubMedWeb of Science
  33. ↵
    1. Scioscia G,
    2. Blanco I,
    3. Burgos F
    , et al. Different dyspnea perception in COPD patients with frequent and infrequent exacerbations. Thorax 2017; 72: 117–121.
    OpenUrlAbstract/FREE Full Text
  34. ↵
    1. Hurst JR,
    2. Donaldson GC,
    3. Perera WR
    , et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 174: 867–874.
    OpenUrlCrossRefPubMedWeb of Science
  35. ↵
    1. Menche J,
    2. Sharma A,
    3. Kitsak M
    , et al. Disease networks. Uncovering disease-disease relationships through the incomplete interactome. Science 2015; 347: 1257601.
    OpenUrlAbstract/FREE Full Text
  36. ↵
    1. Ghiassian SD,
    2. Menche J,
    3. Barabasi AL
    . A DIseAse MOdule Detection (DIAMOnD) algorithm derived from a systematic analysis of connectivity patterns of disease proteins in the human interactome. PLoS Comput Biol 2015; 11: e1004120.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
View this article with LENS
Vol 50 Issue 3 Table of Contents
European Respiratory Journal: 50 (3)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Multi-level differential network analysis of COPD exacerbations
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Multi-level differential network analysis of COPD exacerbations
Guillaume Noell, Borja G. Cosío, Rosa Faner, Eduard Monsó, German Peces-Barba, Alfredo de Diego, Cristobal Esteban, Joaquim Gea, Robert Rodriguez-Roisin, Marian Garcia-Nuñez, Francisco Pozo-Rodriguez, Susana G. Kalko, Alvar Agustí
European Respiratory Journal Sep 2017, 50 (3) 1700075; DOI: 10.1183/13993003.00075-2017

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Multi-level differential network analysis of COPD exacerbations
Guillaume Noell, Borja G. Cosío, Rosa Faner, Eduard Monsó, German Peces-Barba, Alfredo de Diego, Cristobal Esteban, Joaquim Gea, Robert Rodriguez-Roisin, Marian Garcia-Nuñez, Francisco Pozo-Rodriguez, Susana G. Kalko, Alvar Agustí
European Respiratory Journal Sep 2017, 50 (3) 1700075; DOI: 10.1183/13993003.00075-2017
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Abstract
    • Introduction
    • Methods
    • Results
    • Discussion
    • Supplementary material
    • Disclosures
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • COPD and smoking
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Original articles

  • Ambulatory management of secondary spontaneous pneumothorax
  • Systematic assessment of respiratory health in illness susceptible athletes
  • Identifying early PAH biomarkers in systemic sclerosis
Show more Original articles

COPD

  • Sensitisation to recombinant A. fumigatus allergens and outcomes in COPD
  • Detection of COPD in the SUMMIT lung cancer screening cohort
  • Flavonoid intakes inversely associate with COPD in smokers
Show more COPD

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society